Predictors of distant metastasis after combined HDR brachytherapy and external beam radiation for prostate cancer

Journal of Contemporary Brachytherapy

Volumn 5, Issue 3, 2013, Pages 127-133

  Kamrava, Mitchell ^a   Rwigema, Jean Claude ^a   Chung, Melody ^a   Banerjee, Robyn ^a   Wang, Jason ^a   Steinberg, Michael ^a   Demanes, David Jeffrey ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; Distant metastases; High dose rate; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; DISEASE SEVERITY; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 84885761405     PISSN: 1689832X     EISSN: None     Source Type: Journal    
DOI: 10.5114/jcb.2013.37942     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. Cancer Prevention and Control (2012). Retrieved from http://www.cdc.gov/cancer/dcpc/data/men.htm.
2. Forsythe K, Burri R, Stone N et al. Predictors of metastatic disease after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2012; 83: 645-652.
3. Stone NN, Potters L, Davis BJ et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 73: 341-346.
4. Potters L, Morgenstern C, Calugaru E et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005; 173: 1562-1566.
5. Blasko JC, Grimm PD, Sylsvester JE et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000; 57: 273-278.
6. Deutsch I, Zelefsky MJ, Zhang Z et al. Comparison of PSA relapse free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 2010; 9: 313-318.
7. Taira AV, Merrick GS, Galbreath RW et al. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 225-232.
8. D'Amico AV, Moul JW, Carroll PR et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 1376-1383.
9. Zelefsky MJ, Pei X, Chou JF et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011; 60: 1133-1139.
10. Demanes DJ, Rodriguez RR, Altieri GA. High dose rate prostate brachytherapy: the California Endocurietherapy (CET) method. Radiother Oncol 2000; 57: 289-296.
11. Martinez AA, Gonzalez J, Ye H et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79: 363-370.
12. Kotecha R, Yamada Y, Pei X et al. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy 2013; 12: 44-49.
13. Prada PJ, González H, Fernández J et al. Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience. BJU Int 2012; 109: 1787-1793.
14. Hoskin PJ, Colombo A, Henry A et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localized prostate cancer: An update. Radiother Oncol 2013; 107: 325-332.
15. Pötter R, Haie-Meder C, Van Limbergen E et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006; 78: 67-77.
16. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
17. Zhou P, Chen MH, McLeod D et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005; 23: 6992-6998.
18. Skowronek J. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options. J Contemp Brachytherapy 2013; 5: 33-41.
19. Deger S, Boehmer D, Roigas J et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 2005; 47: 441-448.
20. Demanes DJ, Rodriguez RR, Schour L et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005; 61: 1306-1316.
21. Galalae RM, Martinez A, Mate T et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1048-1055.
22. Viani GA, Pellizzon AC, Guimarães FS et al. High dose rate and external beam radiotherapy in locally advanced prostate cancer. Am J Clin Oncol 2009; 32: 187-190.
23. Agoston P, Major T, Fröhlich G et al. Moderate dose escalation with single-fraction high-dose rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients. Brachytherapy 2011; 10: 376-384.